Neurotech International Limited (ASX:NTI) has issued two separate classes of unlisted options, each comprising 11,250,000 securities, as part consideration for joint lead manager services, according to an Appendix 3G lodged with ASX on 17 November 2026.
Key Points
- 11,250,000 unlisted options with an exercise price of A$0.02 were issued on 17 November 2026, expiring 17 November 2028
- A separate class of 11,250,000 unlisted options with an exercise price of A$0.035 were also issued on 17 November 2026, expiring 17 November 2029
- Both classes were issued as part consideration for joint lead manager services, not for cash consideration
- The options relate to a transaction previously announced via an Appendix 3B dated 4 August 2026, with shareholders approving the issue under resolution 8 of the Notice of Meeting released on 1 October 2026
Terms of the Two Unlisted Option Classes Issued on 17 November 2026
The first class of unlisted options carries an exercise price of A$0.02 per option and expires on 17 November 2028. The second class carries an exercise price of A$0.035 per option and expires on 17 November 2029. Both classes are denominated in Australian dollars and, upon exercise, convert into NTI ordinary fully paid shares. Neither class is quoted, nor is intended to be quoted, on ASX. Both classes were issued on 17 November 2026 and each comprises exactly 11,250,000 options, with all securities in each class ranking equally in all respects from their issue date.
Consideration and Shareholder Approval for the Option Issue
The filing states that both classes of unlisted options were provided as part consideration for joint lead manager services, with no cash consideration received by Neurotech International for either class. The issue was previously notified to the market through an Appendix 3B lodged on 4 August 2026, described as a placement or other type of issue. Shareholder approval was obtained under resolution 8 of the Notice of Meeting released to ASX on 1 October 2026, with the material terms of the securities set out in that meeting notice document.
Additional Securities Issued and Issued Capital Note
The filing also discloses that 28,100,294 shares were issued on the same date as this Appendix 3G, being 17 November 2026, as the remaining securities required to complete the transaction referenced in the earlier Appendix 3B. The company noted that, due to ASX form processing, the issued capital figures shown in Part 4 of the form may not be accurate. According to the filing, Neurotech International stated that the correct position, per ASX appendices released on the same date, reflects the additional issuance of 28,100,294 shares and 19,500,000 options.




Please wait processing your request...